Abstract Submission

Our Call-for-Abstracts will open soon.  Below are the guidelines to help you prepare for your submission.  


• Abstracts must be submitted by 12 September 2022, 23:59 hours (Singapore Standard Time, +8.00UTC).  Strictly no extension.

Topics for your submissions:

  1. Epidemiology, Genetics, and Epigenetics
  2. Basic Science and Pathophysiology
  3. Neuroimaging and Neurophysiology
  4. Patient Reported Outcomes and Programs that Support Quality of Life
  5. Disease modifying therapies
  6. Comprehensive Clinical Care
  7. Symptom Management; Rehabilitation Research and Strategies
  8. Mental Health and Psychosocial issues
  9. Advances in Technology and Methods of Care
  10. COVID-19 and patients with MS or its related disorders


Submission Areas Include:

  • Research Reports

These reports present completed original research on pharmacologic agents, therapeutic issues, and innovative services or outcomes of services provided to the MS patient population.

  • Research-in-Progress

These posters represent currently ongoing, uncompleted studies. The author may discuss preliminary results of the studies, provided the research methods have been validated. Topics may include clinical drug studies, therapeutics issues, innovative services, and outcomes.

  • Case Studies

These posters present a description of the evidence-based management and treatment of a patient from the author’s clinical practice with an uncommon presentation and/or clinically challenging scenario, emphasizing steps taken to maximize the likelihood of an optimal outcome.

  • Repeat Presentations

These posters represent findings that have been presented at other meetings, but contain information of interest to clinicians who care for MS patients. These completed studies need to be original research on pharmacologic issues, therapeutic considerations, innovative services, or outcomes related to Multiple Sclerosis.


• Submission via our submission portal which will be launched soon.  You are required to fill in all fields including age, year of graduation and position in the organisation of the first presenting author.  Only the first presenting author is required to submit a short biography.  The rest are optional.

Registration is compulsory
•Submission of an abstract does not constitute registration for the congress. Presenters are required to register for the congress separately.  Registration is compulsory for the publication of the abstracts in Multiple Sclerosis Journal. Those whose abstracts are accepted but did not register and turn up for the congress will not be published.

Typography / Format
• The abstract must be original, submitted online in the respective format: Title, Background, Objective, Methods, Results and Conclusions.
• Use UK spelling. All abbreviations must be clearly defined at least once.
• Type the title using title case (eg. The Title Should be Written Like This)
• The length of the content, excluding title and affiliation, is limited by word count of a total of approximately 300. Figures, tables and references should not be included in the abstract.

To help you plan your abstracts, here are some guides to your word limitations:

  1. Select your topic from a drop-down menu
  2. Title of Abstract
  3. Background (maximum 50 words)
  4. Objective (maximum 30 words)
  5. Methods (maximum 200 words)
  6. Results (maximum 120 words)
  7. Conclusion (maximum 30 words)
  8. Conflict of Interest/Disclosures (no limit)

Contributing Authors
• The first author listed should be the presenting author.
• When more than one author is listed, use the fields for the subsequent authors.
• Any conflict of interest with regards to the abstract/poster should be declared at submission.

Notification of Accepted Abstracts
• Authors of accepted abstracts will be informed by 19 September.  Please check your spam mails and use emails where you could be reached.  Note that some organization may have mail filters that may prevent our emails from reaching you.  

Accepted Authors must register for the congress.  Further information regarding the size of the printed poster will be advised later. 


Legal Disclaimer
• Abstracts are subject to approval by the Scientific Committee.

• The Scientific Committee reserves the right to edit the abstract for publication purposes.
• By submitting your abstract, you (and all the authors involved) agree to have it possibly edited, included and published on the PACTRIMS website and in the Multiple Sclerosis Journal; and release the PACTRIMS organising, scientific and local committee and Secretariat team from all responsibility for the continued accuracy of the information and any withholding copyright issue of the data or information contained within


The best posters will be selected for the following special awards:

  • PACTRIMS Young Investigator Award (USD500)
  • PACTRIMS Best Poster Award (USD500)
  • PACTRIMS Investigator Award (USD500)
  • MSJ-PACTRIMS Investigator Award (USD500)
  • MSJ-PACTRIMS Young Investigator Best Poster Award (USD500)
  • PACTRIMS Best Case Presentation Award (USD50)